Advertisement

Ads Placeholder
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.03
$-0.28(-6.50%)
U.S. Market opens in 0h 55m

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap262.2M
P/E Ratio-5.03
EPS (TTM)$-0.80
ROE2.68%
Fundamental Analysis

AI Price Forecasts

1 Month$4.78
3 Months$0.00
1 Year Target$0.00

EOLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Evolus, Inc. (EOLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 37.83, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.03 and a market capitalization of 262.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-6.50%
5-Day Change
-1.95%
1-Month Change
-2.42%
3-Month Change
-40.03%
6-Month Change
-38.00%
Year-to-Date (YTD) Change
-40.03%
1-Year Change
-64.62%
3-Year Change
-52.36%
5-Year Change
-69.07%
All-Time (Max) Change
-64.96%

Contact Information

949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

3,720 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions